Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

Drake, 2006, Mechanisms of immune evasion by tumors, Adv Immunol, 90, 51, 10.1016/S0065-2776(06)90002-9

Ceeraz, 2013, B7 family checkpoint regulators in immune regulation and disease, Trends Immunol, 34, 556, 10.1016/j.it.2013.07.003

Yaddanapudi, 2013, Cancer vaccines: Looking to the future, Oncoimmunology, 2, e23403, 10.4161/onci.23403

Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027

Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, 2, 261, 10.1038/85330

Francisco, 2010, The PD-1 pathway in tolerance and autoimmunity, Immunol Rev, 236, 219, 10.1111/j.1600-065X.2010.00923.x

Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm0902-1039c

Yokosuka, 2012, Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2, J Exp Med, 209, 1201, 10.1084/jem.20112741

Sanmamed, 2014, Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation, Cancer J, 20, 256, 10.1097/PPO.0000000000000061

Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat Med, 5, 1365, 10.1038/70932

Azuma, 2008, B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells, Blood, 111, 3635, 10.1182/blood-2007-11-123141

Hirano, 2005, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity, Cancer Res, 65, 1089, 10.1158/0008-5472.1089.65.3

Callahan, 2013, At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy, J Leukoc Biol, 94, 41, 10.1189/jlb.1212631

Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med, 369, 134, 10.1056/NEJMoa1305133

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Harding, 2010, The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions, MAbs, 2, 256, 10.4161/mabs.2.3.11641

Nelson, 2010, Development trends for human monoclonal antibody therapeutics, Nat Rev Drug Discov, 9, 767, 10.1038/nrd3229

Chames, 2009, Therapeutic antibodies: successes, limitations and hopes for the future, Br J Pharmacol, 157, 220, 10.1111/j.1476-5381.2009.00190.x

Keefe, 2010, Aptamers as therapeutics, Nat Rev Drug Discov, 9, 537, 10.1038/nrd3141

Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0

Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121

White, 2000, Developing aptamers into therapeutics, J Clin Invest, 106, 929, 10.1172/JCI11325

Eyetech Study Group, 2003, Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results, Ophthalmol, 110, 979, 10.1016/S0161-6420(03)00085-X

Eyetech Study Group, 2002, Preclinical and phase IA clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration, Retina, 22, 143, 10.1097/00006982-200204000-00002

Lázár-Molnár, 2008, Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2, Proc Natl Acad Sci USA, 105, 10483, 10.1073/pnas.0804453105

Cheng, 2013, Structure and interactions of the human programmed cell death 1 receptor, J Biol Chem, 288, 11771, 10.1074/jbc.M112.448126

Da Pieve, 2012, PEGylation and biodistribution of an anti-MUC1 aptamer in MCF-7 tumor-bearing mice, Bioconjug Chem, 23, 1377, 10.1021/bc300128r

Healy, 2004, Pharmacokinetics and biodistribution of novel aptamer compositions, Pharm Res, 21, 2234, 10.1007/s11095-004-7676-4

Terawaki, 2011, IFN-á directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity, J Immunol, 186, 2772, 10.4049/jimmunol.1003208

Orava, 2013, Blocking the attachment of cancer cells in vivo with DNA aptamers displaying anti-adhesive properties against the carcinoembryonic antigen, Mol Oncol, 7, 799, 10.1016/j.molonc.2013.03.005

Krieg, 2002, CpG motifs in bacterial DNA and their immune effects, Annu Rev Immunol, 20, 709, 10.1146/annurev.immunol.20.100301.064842

Krug, 2001, Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells, Eur J Immunol, 31, 2154, 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U

Santulli-Marotto, 2003, Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity, Cancer Res, 63, 7483

McNamara, 2008, Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice, J Clin Invest, 118, 376, 10.1172/JCI33365

Pastor, 2013, CD28 aptamers as powerful immune response modulators, Mol Ther Nucleic Acids, 2, e98, 10.1038/mtna.2013.26

Orava, 2013, A short DNA aptamer that recognizes TNFá and blocks its activity in vitro, ACS Chem Biol, 8, 170, 10.1021/cb3003557

Prodeus, 2014, Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival, Mol Ther Nucleic Acids, 3, e190, 10.1038/mtna.2014.41

Abdul-Wahid, 2012, A focused immune response targeting the homotypic binding domain of the carcinoembryonic antigen blocks the establishment of tumor foci in vivo, Int J Cancer, 131, 2839, 10.1002/ijc.27582

Alam, 2015, FASTAptamer: A Bioinformatic Toolkit for High-throughput Sequence Analysis of Combinatorial Selections, Mol Ther Nucleic Acids, 4, e230, 10.1038/mtna.2015.4

Zuker, 2003, Mfold web server for nucleic acid folding and hybridization prediction, Nucleic Acids Res, 31, 3406, 10.1093/nar/gkg595

Lazar-Molnar, 2011

Zhang, 2004, Structural and functional analysis of the costimulatory receptor programmed death-1, Immunity, 20, 337, 10.1016/S1074-7613(04)00051-2